Search Result

Results for "

small-cell lung carcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Apoptosis (3) Autophagy (3) c-Met/HGFR (4) EGFR (4) MDM-2/p53 (1) p38 MAPK (3) PD-1/PD-L1 (2) PERK (1) Ras (1)
By Research Areas:	Cancer (11) Inflammation/Immunology (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Targets Recommended: Small Interfering RNA (siRNA) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-N6252

Gypenoside XLVI 1 Publications Verification	Others	Cancer
Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum . Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small cell lung carcinoma A549 cell inhibitory activity .

HY-P99052

Tislelizumab 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

HY-110088

SCH529074 1 Publications Verification	MDM-2/p53	Cancer
SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a K_i of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .

HY-10261

Afatinib Maximum Cited Publications 60 Publications Verification BIBW 2992	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-10261A

Afatinib dimaleate Maximum Cited Publications 60 Publications Verification BIBW 2992MA2	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-148260

KRAS G12D inhibitor 16	Ras	Cancer
KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC₅₀ value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .

HY-157231A

HC-5404-Fu	PERK	Cancer
HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cell carcinoma cells to vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs). HC-5404-Fu is promising for research of renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors .

HY-10261D

Afatinib oxalate BIBW 2992 oxalate	EGFR Autophagy Apoptosis c-Met/HGFR Akt	Cancer
Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-10261E

(R)-Afatinib (R)-BIBW 2992	EGFR c-Met/HGFR p38 MAPK	Cancer
(R)-Afatinib ((R)-BIBW 2992) is the Afatinib isomer. Afatinib (HY-10261) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

Cat. No.	Product Name	Target	Research Area

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-P99052

Tislelizumab 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

HY-P99743

Mitumomab	Inhibitory Antibodies	Cancer
Mitumomab is an anti-idiotypic mouse IgG2b monoclonal antibody that mimics the ganglioside GD3. Mitumomab can be used for the research of small-cell lung carcinoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-N6252

Gypenoside XLVI 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Gynostemma pentaphyllum (Thunb.) Makino Cancer	Others
Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum . Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small cell lung carcinoma A549 cell inhibitory activity .

HY-P99052

Tislelizumab 2 Publications Verification	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

Species:	Human (4)
Tag:	His (1) Avi (1) Fc (3)
Source:	HEK293 (4)

Cat. No.	Compare	Product Name	Species	Source

HY-P70809

	CD24 Protein, Human (HEK293, Fc) Signal transducer CD24; small cell lung carcinoma cluster 4 antigen; CD24; CD24A	Human	HEK293
	The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (HEK293, Fc) is the recombinant human-derived CD24 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P70720

	CD24 Protein, Human (S44T, HEK293, Fc) Signal transducer CD24; small cell lung carcinoma cluster 4 antigen; CD24; CD24A	Human	HEK293
	The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (S44T, HEK293, Fc) is the recombinant human-derived CD24 protein, expressed by HEK293 , with C-hFc labeled tag and S44T, , , , mutation.

HY-P72352

	CD24 Protein, Human (Biotinylated, HEK293, Fc-Avi) Signal transducer CD24; small cell lung carcinoma cluster 4 antigen; CD24; CD24A	Human	HEK293
	The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CD24 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

HY-P700401

	CD24 Protein-Nanoparticle, Human (HEK293, His) CD24; CD24 molecule; CD24 antigen (small cell lung carcinoma cluster 4 antigen); signal transducer CD24; CD24A; FLJ22950; FLJ43543; MGC75043	Human	HEK293
	The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (HEK293, His) is the recombinant human-derived CD24 protein, expressed by HEK293 , with N-6*His labeled tag. The total length of CD24 Protein, Human (HEK293, His) is 33 a.a., with molecular weight of 25.7 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

small-cell lung carcinoma

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Natural
Products